-+ 0.00%
-+ 0.00%
-+ 0.00%

BTIG Initiates Coverage On Bright Minds Biosciences with Buy Rating, Announces Price Target of $72

Benzinga·09/08/2025 10:10:43
Listen to the news
BTIG analyst Thomas Shrader initiates coverage on Bright Minds Biosciences (NASDAQ:DRUG) with a Buy rating and announces Price Target of $72.